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of Long-term Shiga 
Toxin–producing 
Escherichia coli
To the Editor: Long-term car-
riage of Shiga toxin–producing Esch-
erichia coli (STEC) can greatly affect 
the social and work lives of infected 
patients. We describe the use of whole-
genome sequencing to assess the risk 
from long-term STEC carriage in a 
patient who had been denied surgery 
because of the infection.
On August 18, 2013, a 64-year-
old woman reporting to be a carrier 
of STEC since March 2013 contacted 
the University Medical Center Lü-
beck, Lubeck, Germany, seeking de-
colonization therapy that had been 
provided to long-term STEC carri-
ers during the 2011 STEC O104:H4 
outbreak (1). STEC had initially been 
identified in the patient during an epi-
sode of watery diarrhea. She currently 
had gonarthrosis grade III, indicating 
the need for a total knee endopros-
thesis; however, the responsible 
orthopedic department had denied 
surgery because of the potential risk 
for development of STEC-associated 
hemolytic uremic syndrome (HUS) 
caused by the perioperative use of 
antimicrobial drug prophylaxis. 
The patient was also rejected for 
surgery at another orthopedic clinic. 
Because of this STEC-associated 
restriction, the patient requested de-
colonization therapy.
Before responding to the request, 
we asked the patient to provide a fe-
cal sample for STEC strain typing. A 
sample provided on August 22, 2013, 
was confirmed positive for STEC by 
culturing an STEC strain on MacCon-
key agar (bioMérieux, Marcy l’Etoile, 
France) that did not grow on selective 
agar (CHROMagar STEC, Mast Diag-
nostika, Reinfeld, Germany) optimized 
for the detection of classical enterohe-
morrhagic E. coli strains. Total DNA 
was extracted from the isolate, and a 
sequencing library was generated by 
using the Nextera XT Sample Prepa-
ration Kit (Illumina, San Diego, CA, 
USA). Sequencing was performed 
(MiSeq Benchtop Sequencer, Illumina) 
in 2 batches of paired 250-bp sequenc-
ing runs. Sequencing reads were fur-
ther analyzed by using the CLC Ge-
nomics Workbench software package 
(CLC bio, Aarhus, Denmark). De novo 
assembly resulted in 120 contigs with 
an average length of 44,331 bp (N50 
= 126,317 bp). A predefined dataset of 
2,456 sequences was aligned with the 
generated contigs in a single step by us-
ing BLAST (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) to determine the alleles 
and subtypes of genes usually used for 
E. coli and STEC strain typing and for 
seropathotype detection.
Presence of a Shiga toxin sub-
type 1a with >99.9% and 100% iden-
tity to the stx1aA and stx1aB subunit 
genes, respectively (GenBank acces-
sion no M19473.1), was confirmed. 
The STEC strain carried genes with 
high homology to the O91 antigen–
encoding operon (GenBank acces-
sion no. AY035396.1) and the H14-
flagellin gene (GenBank accession no. 
AY249998.1). This observation was 
confirmed by a 100% sequence iden-
tity of a 643-bp fragment of the gnd 
gene of the sequenced strain with that 
of a gnd reference sequence of STEC 
O91:H14 (www.corefacility.ca/ecoli_
typer). These 2 sequences are different 
from the gnd sequence of reference 
strain STEC O91:H21. In vitro mul-




sequence type (ST) 33. These data 
were used for risk assessment.
Only strains displaying serotype 
O91:H21 and a single O91:H10 iso-
late have been associated with HUS in 
humans (3,4). ST33, identified in the 
patient in this study, has not been asso-
ciated with HUS in humans despite be-
ing the most frequently identified ST 
of O91 STEC strains in humans (3). In 
addition, the identified strain carried 
only Shiga toxin 1a, whereas the HUS-
associated strain HUSEC034 of sero-
type O91:H21 carried Shiga toxins 1a, 
2a, and 2d (5). This data indicated the 
patient strain was a seropathotype D 
strain (6) with a relative low risk for 
HUS development in the patient.
The assumption that the patient 
strain had low pathogenicity was fur-
ther corroborated by the analysis of ad-
ditional marker genes (6–9) indicating 
the lack of pathogenicity islands as-
sociated with high virulence of STEC 
in humans. None of the 25 marker 
genes suggested for the LEE locus or 
pathogenicity islands OI-36, OI-43, 
OI-44, OI-48, OI-50, OI-57, OI-71 or 
OI-122 were identified in the patient 
strain, whereas most of these markers 
could be detected in highly pathogen-
ic STEC/enterohemorrhagic E. coli 
strains used to establish the method 
for identifying markers (online Tech-
nical Appendix, wwwnc.cdc.gov/EID/
article/20/4/13-1782-Techapp1.pdf).
After completing the STEC risk 
assessment, we advised the patient’s 
general practitioner that antimicrobial 
drug prophylaxis could be adminis-
tered for surgery with a low calcu-
lated risk for HUS development, as 
observed for other non-O157 strains 
(1,10). In addition, we described our 
experience with 4 long-term carriers 
of STEC O91:H14 strains; the patients 
had been decolonized of STEC by the 
use of azithromycin decolonization 
therapy (data not shown).
The patient was added to a wait-
ing list for surgery, and she elected to 
receive azithromycin as experimental 
decolonization therapy while awaiting 
surgery. Azithromycin was adminis-
tered orally for 3 days (500 mg/day); 
fecal specimens on post-treatment 
days 7, 14, and 21 were negative by 
Shiga toxin ELISA. In addition, an stx-
specific PCR using enrichment broth 
confirmed the sustainable eradication 
of the STEC infection. Our findings 
show that whole-genome sequenc-
ing can be used in the diagnostic pro-
cess for long-term STEC carriers and 
might extend or replace other methods 
used for risk assessment (6–8,10) and 
treatment decision guidance.
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